Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza today is providing restated financials to reflect: The classification of Lonza’s Specialty Ingredients (LSI) business […]
continue readingLonza Announces Results of the 2021 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A dividend of CHF 3.00 per share will be paid out starting from 12 May 2021 […]
continue readingLonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)
. Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A new large-scale facility with the latest manufacturing technology in Visp (CH), will expand capacity by six 20,000L bioreactors to meet increasing market demand for biologics […]
continue readingLonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complex The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules The investment is supported by a long-term collaboration and capital contribution with a major biopharmaceutical partner The new manufacturing complex is designed to accommodate future small molecule […]
continue readingLonza finalise la cession de deux sites à NextPharma
Finalisation de la vente des sites Lonza de Ploermel (FR) et d’Edimbourg (UK) Un processus de transfert de propriété sans heurts reste une priorité Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza : "La cession stratégique de nos sites de Ploermel et d’Édimbourg permettra à NextPharma de bénéficier de synergies […]
continue readingLonza Completes Divestment of Two Sites to NextPharma
Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In […]
continue readingLonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right […]
continue readingLonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business
Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong LPBN performance: 12.2%2 sales growth and 32.1% CORE EBITDA margin Production of the […]
continue readingNextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets […]
continue readingLonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with a global biopharma company will generate around 200 new jobs in Visp (CH) biopark, with […]
continue reading